396 related articles for article (PubMed ID: 17966590)
1. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
3. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
Parra C; González JM; Castañeda E; Fiorentino S
Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
[TBL] [Abstract][Full Text] [Related]
5. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
Maitta RW; Datta K; Pirofski LA
Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
[TBL] [Abstract][Full Text] [Related]
7. [Recognition of intact cells from Cryptococcus neoformans by the anti-glucuronoxylomannan 4B3 monoclonal antibody].
Gato Armas R; Martínez Machín G; Rodríguez Sánchez H; Otero González A; Sarracent Pérez J; Illnait Zaragozi MT
Rev Cubana Med Trop; 2006; 58(2):159-61. PubMed ID: 23427436
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
9. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
10. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection.
Abadi J; Pirofski La
J Infect Dis; 1999 Sep; 180(3):915-9. PubMed ID: 10438394
[TBL] [Abstract][Full Text] [Related]
11. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
12. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
13. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
[TBL] [Abstract][Full Text] [Related]
14. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
15. Structural studies of the capsular polysaccharide of a non-neoformans Cryptococcus species identified as C. laurentii, which was reclassified as Cryptococcus flavescens, from a patient with AIDS.
Ikeda R; Maeda T
Carbohydr Res; 2004 Feb; 339(3):503-9. PubMed ID: 15013387
[TBL] [Abstract][Full Text] [Related]
16. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
Valadon P; Nussbaum G; Oh J; Scharff MD
J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
[TBL] [Abstract][Full Text] [Related]
17. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
18. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
[TBL] [Abstract][Full Text] [Related]
19. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
20. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]